Sanara MedTech Inc.(SMTI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,215 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in SMTI
Events flagged as statistical outliers against SMTI's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
SMTI quality score jumped 17 points (33→51) on a new filing
View source filing →
SMTI Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Sanara MedTech Inc. (SMTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SMTI at 38.0/100 on a 32-signal composite quality model, placing it at rank #2,215 of 2,962 stocks — the bottom half of the AI-ranked universe. SMTI scores in the top quartile across revenue growth (84.3). Areas of concern include balance sheet strength (6.0) and profitability (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Sanara MedTech Inc. reports quarterly revenue of $28.1M, net income of $-452.9K, an operating margin of 6.3%. Top institutional holders of SMTI by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, ROYAL BANK OF CANADA, based on the most recent SEC filings. SMTI trades on the Nasdaq exchange and files with the SEC under CIK 714256. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sanara MedTech Inc. directly from SEC EDGAR. Sanara MedTech Inc.'s 13F Pro composite quality score has ranged between 33 and 65 since 2023, currently 38.0 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$28.1M
Net Income
Q2 2026
$-452.9K
Free Cash Flow
Q2 2026
$2.0M
Operating Margin
Q2 2026
6.3%
ROIC
Q2 2026
13.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+19.0% YoYNet Income
-288.7% YoYOperating Income
+480.3% YoYEPS (Diluted)
-282.5% YoYTotal Assets
-17.2% YoYTotal Debt
+49.8% YoYOp. Cash Flow
+28634.4% YoYFree Cash Flow
+1041.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $103.1M +19.0% | $86.7M +33.4% | $65.0M +41.8% | $45.8M +89.9% | $24.1M +54.9% | $15.6M |
| Net Income | $-37.6M -288.7% | $-9.7M -124.6% | $-4.3M +45.8% | $-7.9M -0.2% | $-7.9M -78.2% | $-4.4M |
| Operating Income | $7.3M +480.3% | $1.3M +129.9% | $-4.2M +66.3% | $-12.5M -69.7% | $-7.4M -46.5% | $-5.0M |
| EPS (Diluted) | $-4.36 -282.5% | $-1.14 -119.2% | $-0.52 +48.0% | $-1.00 | — | $-0.76 |
| Total Assets | $72.9M -17.2% | $88.1M +19.3% | $73.9M +21.0% | $61.0M +67.7% | $36.4M +270.4% | $9.8M |
| Total Debt | $46.0M +49.8% | $30.7M +198.7% | $10.3M | — | — | — |
| Operating Cash Flow | $6.8M +28634.4% | $-23.8K +99.3% | $-3.2M +41.6% | $-5.6M -15.4% | $-4.8M -19.3% | $-4.0M |
| Free Cash Flow | $2.2M +1041.1% | $-229.6K +93.5% | $-3.5M +38.4% | $-5.7M -14.3% | $-5.0M -8.9% | $-4.6M |
Get alerted when SMTI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sanara MedTech Inc. including:
Top Institutional Holders of SMTI
BlackRock, Inc.
$5.9M248,827 shVANGUARD CAPITAL MANAGEMENT LLC
$4.6M194,897 shROYAL BANK OF CANADA
$3.1M130,995 shStonebridge Wealth Management, LLC
$3.1M129,452 shAQR CAPITAL MANAGEMENT LLC
$2.6M112,207 shGEODE CAPITAL MANAGEMENT, LLC
$2.1M89,179 shGOLDMAN SACHS GROUP INC
$1.8M74,198 shRENAISSANCE TECHNOLOGIES LLC
$1.6M67,400 shSTATE STREET CORP
$1.5M63,469 shSquarepoint Ops LLC
$1.3M53,811 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $5.9M | 248,827 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.6M | 194,897 |
| ROYAL BANK OF CANADA | $3.1M | 130,995 |
| Stonebridge Wealth Management, LLC | $3.1M | 129,452 |
| AQR CAPITAL MANAGEMENT LLC | $2.6M | 112,207 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.1M | 89,179 |
| GOLDMAN SACHS GROUP INC | $1.8M | 74,198 |
| RENAISSANCE TECHNOLOGIES LLC | $1.6M | 67,400 |
| STATE STREET CORP | $1.5M | 63,469 |
| Squarepoint Ops LLC | $1.3M | 53,811 |
Companies Similar to SMTI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Centessa Pharmaceuticals plc
Usio, Inc.
NovoCure Ltd
HARROW, INC.
MACROGENICS INC
Fulgent Genetics, Inc.
Inogen Inc
Axogen, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SMTI on your watchlist
Track score changes the day Sanara MedTech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SMTI a good stock to buy?
13F Pro's AI-powered analysis of Sanara MedTech Inc. (SMTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SMTI are available on the SMTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SMTI is classified as a small company.
Which hedge funds own SMTI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SMTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sanara MedTech Inc.'s investment landscape.